GlassScriptPhysician profile
Sarah Youssef
NPI 1003827957
$2,243.43
in general payments reported to CMS, 2019-2025
20 companies · $679 in 2025
The $679 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.04 · 2023: $752 · 2024: $780 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,211.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $442.36 | 2023-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $353.84 | 2023-2025 | Rexulti |
| Abbvie INC. | $329.04 | 2023-2025 | Vraylar |
| Corium, LLC | $249.75 | 2023-2025 | Azstarys |
| Biosense Webster, INC. | $138.83 | 2024 | Carto 3 |
| Alkermes, INC. | $123.63 | 2023-2025 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $98.46 | 2023 | Qelbree |
| Tris Pharma INC | $84.24 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $72.62 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $70.52 | 2023-2024 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $58.29 | 2022-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $38.08 | 2022-2023 | Ingrezza |
| Collegium Pharmaceutical, INC. | $36.36 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $31.34 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $28.36 | 2025 | Fanapt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.49 | 2024 | Trintellix |
| Axsome Therapeutics, INC. | $19.11 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.74 | 2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $13.76 | 2024 | |
| Biogen, INC. | $13.61 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.